Rapport Therapeutics, Inc.
RAPP evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $2.11B
- Lead Asset:
- rap-219 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for RAPP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RAPP
Rapport Therapeutics, Inc. (RAPP) is a clinical-stage biotechnology company developing small molecule precision medicines for neurological and psychiatric disorders, with its lead candidate RAP-219 in Phase 3 for focal seizures and Phase 2 for bipolar I disorder.
Key risk: No revenue, net loss
BioSniper Score
Based on 4 of 6 signals
Market Cap
$2.11B
Cash Runway
—
Lead Asset
rap-219 (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 5 clinical trials for Rapport Therapeutics, Inc..
Rapport Therapeutics, Inc. (RAPP) is a clinical-stage biotechnology company developing small molecule precision medicines for neurological and psychiatric disorders, with its lead candidate RAP-219 in Phase 3 for focal seizures and Phase 2 for bipolar I disorder.
- Lead candidate RAP-219 is in Phase 3 for focal seizures and Phase 2 for bipolar I disorder [pipeline].
- In a Phase 2a trial, RAP-219 achieved a 77.8% reduction in clinical seizures (p=0.01) and 24% seizure freedom (p<0.0001) [news · 2025-09-08].
- Cash & equivalents were $63.6M as of 2026-06-30, with $0.0M revenue and a net loss of -$56.6M [sec].
- Shareholders' equity stood at $422.9M as of 2026-06-30 [sec].
- Key clinical readouts for RAP-219 are expected in fall 2026 [news · 2026-09-22].
What works
- RAP-219 demonstrated statistically significant seizure reduction in Phase 2a, supporting advancement to Phase 3 [news · 2025-09-08].
- The company has a strong cash position of $63.6M as of 2026-06-30, providing runway for ongoing trials [sec].
- RAP-219 is being studied across multiple indications (focal seizures, bipolar I disorder), diversifying pipeline risk [pipeline].
What to weigh
- The company has no revenue ($0.0M as of 2026-06-30) and a net loss of -$56.6M, typical for a pre-commercial biotech [sec].
- RAP-219 faces competition from 11 other programs in focal seizures/bipolar disorder, including Phase 3 candidates from Bristol-Myers Squibb [pipeline].
- The company's valuation is described as pricing in 'significant success' ahead of pivotal data, implying high expectations [news · 2026-09-23].
From the filings
Quoted directly from source documents.
Phase 2a trial of RAP-219 met primary endpoint with high statistical significance
“Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well tolerated”
News · September 8, 2025
77.8% reduction in clinical seizures and 24% seizure freedom
“Patients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for the 8-week treatment period (p<0.0001)”
News · September 8, 2025
Catalyst timeline
- 2026-06-05 · Phase 3 start for RAP-219 in focal seizures — A Phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety in adult participants with focal seizures.
- 2025-07-25 · Phase 2 start for RAP-219 in bipolar I disorder — A Phase 2, double-blind, placebo-controlled study evaluating efficacy and safety for acute treatment of manic episodes associated with bipolar I disorder.
Risks & what to watch (3)›
Key risks
- No revenue, net loss — Company has $0.0M revenue and -$56.6M net loss as of 2026-06-30, typical pre-commercial risk [sec].
- Competitive landscape — RAP-219 faces 11 competitors, including Phase 3 programs from Bristol-Myers Squibb [pipeline].
- Valuation expectations — Analyst notes valuation 'prices in significant success' ahead of pivotal data [news · 2026-09-23].
What to watch
- Phase 3 results for RAP-219 in focal seizures, expected in fall 2026 [news · 2026-09-22].
- Phase 2 data for RAP-219 in bipolar I disorder, with trial started 2025-07-25 [catalyst].
- Cash runway and any new financing rounds given $63.6M cash and ongoing trials [sec].
Sources: Catalysts · News · Pipeline · Generated October 10, 2026 · How we verify sources →
Run Rapport Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Rapport Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.09 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
0 buys · 26 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 14.6%
- Days to cover
- 10.6
- Shares short
- 3,849,519
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RAPP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Rapport Therapeutics, Inc.?
Rapport Therapeutics, Inc. (RAPP) is a clinical-stage biotechnology company developing small molecule precision medicines for neurological and psychiatric disorders, with its lead candidate RAP-219 in Phase 3 for focal seizures and Phase 2 for bipolar I disorder.
What is Rapport Therapeutics, Inc.'s lead drug candidate?
Rapport Therapeutics, Inc.'s most advanced tracked candidate is rap-219 (Phase 3) for Focal Seizure; Bipolar 1 Disorder; Focal Epilepsy.
Who is the CEO of Rapport Therapeutics, Inc.?
Mr. Abraham N. Ceesay M.B.A. is the chief executive officer of Rapport Therapeutics, Inc. (RAPP).
Where is Rapport Therapeutics, Inc. headquartered?
Rapport Therapeutics, Inc. (RAPP) is headquartered in Boston, MA, United States.
What therapeutic areas does Rapport Therapeutics, Inc. focus on?
Rapport Therapeutics, Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.